- Home
- CUE vs ADAG Comparison
CUE vs ADAG Comparison
Compare CUE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ADAG
- Stock Information
- Founded
- CUE 2014
- ADAG 2011
- Country
- CUE United States
- ADAG China
- Employees
- CUE N/A
- ADAG N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ADAG Health Care
- Exchange
- CUE Nasdaq
- ADAG Nasdaq
- Market Cap
- CUE 48.0M
- ADAG 91.4M
- IPO Year
- CUE 2018
- ADAG 2021
- Fundamental
- Price
- CUE $0.68
- ADAG $1.88
- Analyst Decision
- CUE Strong Buy
- ADAG Strong Buy
- Analyst Count
- CUE 3
- ADAG 1
- Target Price
- CUE $3.00
- ADAG $8.00
- AVG Volume (30 Days)
- CUE 311.2K
- ADAG 92.2K
- Earning Date
- CUE 08-13-2025
- ADAG 07-24-2025
- Dividend Yield
- CUE N/A
- ADAG N/A
- EPS Growth
- CUE N/A
- ADAG N/A
- EPS
- CUE N/A
- ADAG N/A
- Revenue
- CUE $7,991,000.00
- ADAG $103,204.00
- Revenue This Year
- CUE N/A
- ADAG $6,488.89
- Revenue Next Year
- CUE $23.84
- ADAG $57.50
- P/E Ratio
- CUE N/A
- ADAG N/A
- Revenue Growth
- CUE 13.83
- ADAG N/A
- 52 Week Low
- CUE $0.45
- ADAG $1.33
- 52 Week High
- CUE $1.99
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- CUE 47.91
- ADAG 44.87
- Support Level
- CUE $0.65
- ADAG $1.74
- Resistance Level
- CUE $0.71
- ADAG $2.10
- Average True Range (ATR)
- CUE 0.08
- ADAG 0.10
- MACD
- CUE 0.00
- ADAG -0.02
- Stochastic Oscillator
- CUE 38.62
- ADAG 16.67
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.